| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/12/1997 | EP0489048B1 Inhibition of tumor growth by blockade of the protein c system |
| 03/12/1997 | EP0409940B1 Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| 03/12/1997 | EP0378671B1 Insulinomimetic and insulin receptor binding site peptides |
| 03/12/1997 | CN1145077A Immuno-stimulatory monoclonal antibodies |
| 03/12/1997 | CN1145076A Prostaglandin I2 receptor |
| 03/12/1997 | CN1145075A Antagonist's of endothelin receptors |
| 03/12/1997 | CN1145074A Carbamoylmethylurea derivative |
| 03/12/1997 | CN1145033A Human therapeutic uses of BPI protein products |
| 03/12/1997 | CN1145032A Monoclonal anbibodies which bind to tumor rejection antigen precursor MAGE-1, recombinant MAGE-1, and MAGE-1 derived immunogenic peptides |
| 03/12/1997 | CN1144694A External-applied interferon medicine |
| 03/12/1997 | CN1144693A Nerve injury recovery preparation |
| 03/12/1997 | CN1144654A Insulin paper preparation |
| 03/11/1997 | US5610308 Process for preparing intermediates for thrombin inhibitors |
| 03/11/1997 | US5610297 Inhibitors of serine protease and cysteine protease |
| 03/11/1997 | US5610288 Antisense polynucleotide inhibition of epidermal human growth factor receptor expression |
| 03/11/1997 | US5610286 DNA's encoding natural killer cell enhancing factor |
| 03/11/1997 | US5610285 Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
| 03/11/1997 | US5610284 Method of purification of human BCDF |
| 03/11/1997 | US5610281 Monoclonal antibody which specifically binds to human e-cadherin |
| 03/11/1997 | US5610279 Human TNF receptor |
| 03/11/1997 | US5610276 Determination whether a cell is cancerous |
| 03/11/1997 | US5610271 Kappa receptor selective opioid peptides |
| 03/11/1997 | US5610190 Retroviral protease inhibitors |
| 03/11/1997 | US5610183 Phenylglycine derivatives pharmaceutical compositions containing them and their use in therapy |
| 03/11/1997 | US5610148 Macroscopically oriented cell adhesion protein for wound treatment |
| 03/11/1997 | US5610147 Heating |
| 03/11/1997 | US5610146 2,3-disubstituted isoxazolidines, a process for their preparation, agents containing them, and their use |
| 03/11/1997 | US5610145 Carbamate stereoisomers |
| 03/11/1997 | US5610144 Pyrrolidine and thiazolidine derivatives, their preparation and medicaments containing them |
| 03/11/1997 | US5610143 Antibiotics GE 37468 A, B and C |
| 03/11/1997 | US5610142 Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids |
| 03/11/1997 | US5610141 Cell division stimulant |
| 03/11/1997 | US5610140 Bradykinin receptor antagonists with neurokinin receptor blocking activity |
| 03/11/1997 | US5610139 Peptide from horseshoe crab extract, antibiotic, staphylococcus |
| 03/11/1997 | US5610138 Mixture of gonadotrophins and growth hormone |
| 03/11/1997 | US5610137 Transgenic, cross-linked hemoglobin |
| 03/11/1997 | US5610136 Administering chorionic gonadotropin |
| 03/11/1997 | US5610134 Treatment of congestive heart failure |
| 03/11/1997 | US5610067 Method of preparing plasmid having both expressing ability of retroviral gene and processing ability after translation, and resultant plasmid and expression products |
| 03/11/1997 | US5610059 Etiological agent for porcine enteritis |
| 03/11/1997 | US5610057 Monoclonal antibody specific for IgA receptor |
| 03/11/1997 | US5610056 Generation of erythroid cells from hematopoietic stem cells |
| 03/11/1997 | US5610054 Enzymatic RNA molecule targeted against Hepatitis C virus |
| 03/11/1997 | US5610050 Methods of preventing viral replication |
| 03/11/1997 | US5610047 Trehalose |
| 03/11/1997 | US5610031 B1k chain of laminin and methods of use |
| 03/11/1997 | US5610021 Compositions and methods for identification and use of soluble complex forms of osteogenic proteins |
| 03/11/1997 | US5610019 Methods of detecting phospholipid transfer activity and kits therefor |
| 03/11/1997 | US5610018 Mitogenic signal transduction pathway |
| 03/11/1997 | US5610013 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors |
| 03/11/1997 | US5610011 Virulence-encoding DNA sequences of Strepococcus suis and related products and methods |
| 03/11/1997 | US5609871 Microencapsulating enteric coating |
| 03/11/1997 | US5609870 Antisecretory, immunology |
| 03/11/1997 | US5609869 For use in diagnosis and therapy |
| 03/11/1997 | US5609868 Pharmaceutical compositions comprising hybrid α-interferon |
| 03/11/1997 | US5609864 Polyvinylpyrrolidone iodine |
| 03/11/1997 | CA2109435C Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals |
| 03/11/1997 | CA2099263C Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals |
| 03/11/1997 | CA2015505C Polyamines and polypeptides useful as antagonists of excitatory amino acid neurotransmitters and/or as blockers of calcium channels |
| 03/11/1997 | CA1338981C Biologically active proteins and a method for their production |
| 03/06/1997 | WO1997008560A1 QUANTITATION OF p97 TO DIAGNOSE AND MONITOR ALZHEIMER'S DISEASE |
| 03/06/1997 | WO1997008324A1 Methods for enhancing the production of interferon in cell culture |
| 03/06/1997 | WO1997008321A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 03/06/1997 | WO1997008319A1 Genetic alterations related to familial alzheimer's disease |
| 03/06/1997 | WO1997008318A2 Compounds and methods for treatment and diagnosis of prostate cancer |
| 03/06/1997 | WO1997008314A2 Telomere repeat binding factor and diagnostic and therapeutic use thereof |
| 03/06/1997 | WO1997008313A1 Variants of vascular endothelial cell growth factor, their uses, and processes for their production |
| 03/06/1997 | WO1997008311A1 Novel procollagens |
| 03/06/1997 | WO1997008310A1 Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof |
| 03/06/1997 | WO1997008309A2 Ribozyme therapy for hepatitis b infections |
| 03/06/1997 | WO1997008308A1 Batten disease gene |
| 03/06/1997 | WO1997008300A1 Crystalline zap family proteins |
| 03/06/1997 | WO1997008292A1 Methods for enhancing the production of viral vaccines in cell culture by interferon suppression |
| 03/06/1997 | WO1997008205A1 Antibodies having two or more specificities for the selective elimination of cells in vivo |
| 03/06/1997 | WO1997008203A1 Structural mimics of rgd-binding sites |
| 03/06/1997 | WO1997008202A1 Antisecretory factor peptides regulating pathological permeability changes |
| 03/06/1997 | WO1997008201A1 Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor |
| 03/06/1997 | WO1997008200A1 Erythropoietin binding protein useful for regulation of erythropoiesis and an assay for determination thereof |
| 03/06/1997 | WO1997008199A2 Antimicrobial cationic peptides and methods of screening for the same |
| 03/06/1997 | WO1997008197A1 Dna sequence coding for a polypeptide which enhances virus infection of host insects |
| 03/06/1997 | WO1997008196A1 Neurturin and related growth factors |
| 03/06/1997 | WO1997008195A1 Ubiquitin conjugating enzymes having transcriptional repressor activity |
| 03/06/1997 | WO1997008193A1 Acylated oligopeptide derivatives having cell signal inhibiting activity |
| 03/06/1997 | WO1997008191A1 Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin |
| 03/06/1997 | WO1997008184A1 Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators |
| 03/06/1997 | WO1997008180A1 Method to improve the biological and antiviral activity of protease inhibitors |
| 03/06/1997 | WO1997008145A1 Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| 03/06/1997 | WO1997007828A1 Therapy for cellular accumulation in chronic inflammatory diseases |
| 03/06/1997 | WO1997007827A1 Gab1, A Grb2 BINDING PROTEIN, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME |
| 03/06/1997 | WO1997007824A1 Medicine comprising hgf gene |
| 03/06/1997 | WO1997007820A1 Remedy for heart diseases |
| 03/06/1997 | WO1997007819A1 Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated |
| 03/06/1997 | WO1997007816A1 Solution containing igf-i |
| 03/06/1997 | WO1997007815A2 Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| 03/06/1997 | WO1997007814A1 Method and composition for enhanced parenteral nutrition |
| 03/06/1997 | WO1997007813A1 Fertility agent |
| 03/06/1997 | WO1997007809A1 Sulfated disaccharide inhibitors of selectins methods for synthesis and therapeutic use |
| 03/06/1997 | WO1997007808A1 Chimeric antiviral agents which incorporate rev binding nucleic acids |
| 03/06/1997 | WO1997007791A1 Use of aminoadamantane compounds as immunoregulators |
| 03/06/1997 | WO1997007787A1 Oral cyclosporin formulations |